Abstract:Background: In this second part of a two-part paper, we intend to demonstrate the impact of the previously proposed advanced quality control pipeline. To understand its benefit and challenge the proposed methodology in a real scenario, we chose to compare the outcome when applying it to the analysis of two patient populations with a significant but highly different types of fatigue: COVID19 and multiple sclerosis (MS). Experimental: 31P-MRS was performed on a 3T clinical MRI, in 19 COVID19 patients, 38 MS patients, and 40 matched healthy controls. Dynamic acquisitions using an MR-compatible ergometer ran over a rest(40s), exercise(2min), and a recovery phase(6min). Long and short TR acquisitions were also made at rest for T1 correction. The advanced data quality control pipeline presented in part 1 is applied to the selected patient cohorts to investigate its impact on clinical outcomes. We first used power and sample size analysis to estimate objectively the impact of adding QCS. Then, comparisons between patients and healthy control groups using validated QCS were performed using unpaired T-tests or Mann-Whitney tests (p<0.05).Results: The application of the QCS resulted in increased statistical power, changed the values of several outcome measures, and reduced variability (SD). A significant difference was found between the T1PCr and T1Pi of MS patients and healthy controls. Furthermore, the use of a fixed correction factor led to systematically higher estimated concentrations of PCr and Pi than when using individually corrected factors. We observed significant differences between the two patient populations and healthy controls for resting [PCr] -- MS only, [Pi], [ADP], [H2PO4-] and pH -- COVID19 only, and post-exercise [PCr],[Pi] and [H2PO4-] - MS only. The dynamic indicators $\tau$PCr, $\tau$Pi, ViPCr and Vmax were reduced for COVID19 and MS patients compared to controls. Conclusion: Our results show that QCS in dynamic 31P-MRS studies results in smaller data variability and therefore impacts study sample size and power. Although QCS resulted in discarded data and therefore reduced the acceptable data and subject numbers, this rigorous and unbiased approach allowed for proper assessment of muscle metabolites and metabolism in patient populations. The outcomes include an increased metabolite T1, which directly affect the T1 correction factor applied to the amplitudes of the metabolite, and a prolonged $\tau$PCr indicating reduced muscle oxidative capacity for patients with MS and COVID19.

Neuroenergetic alterations in neurodegenerative diseases: A systematic review and meta-analysis of in vivo31P-MRS studies

Systematic review of 31P-magnetic resonance spectroscopy studies of brain high energy phosphates and membrane phospholipids in aging and Alzheimer's disease

Studies on Changes of Brain Energy Metabolism in Diabetic Rats by 31 P Magnetic Resonance Spectroscopy

Applications of magnetic resonance spectroscopy in diagnosis of neurodegenerative diseases: A systematic review

Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson’s Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T

Magnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis

Frontal–temporal regional differences in brain energy metabolism and mitochondrial function using 31P MRS in older adults

Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease

Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis

Magnetic resonance spectroscopy with transcranial direct current stimulation to explore the underlying biochemical and physiological mechanism of the human brain: A systematic review

Investigating Muscle Function after Stroke Rehabilitation with 31P-MRS: A Preliminary Study

Multimodal assessment of mitochondrial function in Parkinson's disease

Mapping Age Differences in Brain Energy Metabolites and Metabolic Markers of Cellular Membrane Production and Degradation With 31P Magnetic Resonance Spectroscopy

Impaired oxygen extraction and adaptation of intracellular energy metabolism in cerebral small vessel disease

An integrated strategy for evaluation of metabolic and oxidative defects in neurodegenerative illness using magnetic resonance techniques

Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.

Cerebral phosphoester signals measured by 31P magnetic resonance spectroscopy at 3 and 7 Tesla

Alteration of skeletal muscle energy metabolism assessed by 31P MRS in clinical routine, part 2: Clinical application

Magnetic Resonance Elastography in the Study of Neurodegenerative Diseases

Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer's Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype

Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy